XML 25 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 22,954 $ 45,006
Short-term investments 147,355 166,864
Accounts receivable, net 32,917 30,424
Inventory 23,969 13,294
Income taxes receivable 6,395 4,614
Prepaid expenses 1,182 1,132
Other current assets 2,657 2,267
Total current assets 237,429 263,601
Deferred income taxes, net 214 8,530
Intangible assets, net 299,606 342,455
Goodwill 103,370 105,673
Commercial license and other economic rights 67,291 10,182
Property and equipment, net 15,607 12,482
Operating lease assets 6,062 10,914
Finance lease assets 3,393 4,095
Equity method investment in Primrose Bio 12,595 0
Other investments 35,726 3,000
Other assets 5,923 1,736
Total assets 787,216 762,668
Current liabilities:    
Accounts payable 2,427 5,307
Accrued liabilities 12,467 15,681
Current contingent liabilities 256 57
Deferred revenue 1,222 355
Current operating lease liabilities 403 670
Current finance lease liabilities 7 45
2023 convertible senior notes, net 0 76,695
Total current liabilities 16,782 98,810
Long-term deferred revenue 1,444 44
Long-term contingent liabilities 2,942 3,456
Deferred income taxes, net 31,622 30,615
Long-term operating lease liabilities 5,755 10,336
Other long-term liabilities 27,758 21,922
Total liabilities 86,303 165,183
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2023 and 2022 0 0
Common stock, $0.001 par value; 60,000 shares authorized; 17,556 and 16,951 shares issued and outstanding at December 31, 2023 and 2022, respectively 18 17
Additional paid-in capital 198,696 147,590
Accumulated other comprehensive loss (817) (984)
Retained earnings 503,016 450,862
Total stockholders’ equity 700,913 597,485
Total liabilities and stockholders’ equity $ 787,216 $ 762,668